Chiesi Group Completes Acquisition of KalVista Pharmaceuticals; Stock Delisted
Summary
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash, resulting in KalVista's delisting from Nasdaq.
Key Events
-
Acquisition Completed
Chiesi Group has successfully completed its tender offer and subsequent merger to acquire KalVista Pharmaceuticals, Inc.
-
Tender Offer Results
Approximately 77.8% of KalVista's outstanding shares were validly tendered and accepted for payment at $27.00 per share, satisfying the minimum condition.
-
Cash Payout for Remaining Shares
All outstanding shares not tendered were converted into the right to receive $27.00 per share in cash.
-
Delisting from Nasdaq
As a result of the merger, KalVista's common stock has ceased trading on the Nasdaq Global Market.
Analysis
This filing confirms the successful completion of Chiesi Group's tender offer and subsequent merger, making KalVista Pharmaceuticals a wholly-owned subsidiary. This is a definitive, thesis-altering event as KalVista's common stock has ceased trading on the Nasdaq Global Market, providing a cash exit for shareholders at $27.00 per share.
At the time of this filing, KALV was trading at $27.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $27.00. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.